Nalu Announces Publication of Results from COMFORT 2 Randomized Control Trial (RCT) Making Nalu the First Permanent PNS Device to Demonstrate Level-1 Clinical Evidence
The results of COMFORT 2, the second Nalu Medical Peripheral Nerve Stimulation (PNS) RCT, were published on July 30th, 2025, in the peer-reviewed journal Chronic Pain & Management and are available here. These results confirm the positive clinical outcomes from the COMFORT trial, the first Nalu PNS RCT, and provide the first Level-1 confirmatory evidence for a permanently implanted PNS device for treating chronic pain.
Nalu Announces Publication of the Largest Long-Term Report of Real-World Data (RWD) on a Permanent PNS Device
Publication of the Nalu Real-World Data (RWD) paper in the Chronic Pain and Management Journal is a significant milestone, establishing Nalu peripheral nerve stimulation (PNS) as a medically necessary treatment for chronic pain.1
Nalu Expands MRI-Conditional Labeling for Peripheral Nerve Stimulation with FDA Clearance for Whole-Body MRI
Nalu Medical announces the FDA clearance for expanded labeling of its Peripheral Nerve Stimulation (PNS) System, now approved for whole-body MRI-conditional use. This clearance provides physicians with greater flexibility in treating chronic pain, minimizing MRI-related limitations. With the Nalu Neurostimulation System's new and expanded MRI-conditional status, pain specialists can confidently offer personalized care without compromising future diagnostic imaging needs.
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing. The round was led by a new investor, Novo Holdings (Novo). Also participating in the round were all of the Nalu existing significant investors: Gilde Healthcare, MVM Partners, Endeavor Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners. The proceeds from this financing will be used to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.
Nalu Medical, Inc. Ranked Number 19 Fastest Growing Company in North America in the 2023 Deloitte Technology Fast 500™
Nalu Medical today announced that it ranked number 19 in the 2023 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Within the life sciences category, the company ranked number 7. Nalu Medical revenue grew 9,623% during the period from 2019 to 2022.
